Bayer has revised some financial estimates for the year 2025, highlighting better-than-expected performance in its pharmaceuticals division. In a statement, the company said it now projects group sales, with currency adjustment, between 46 billion and 48 billion euros (US$ 52.5 billion and US$ 54.8 billion), an increase from the previous forecast of 45 billion to 47 billion euros. Adjusted Ebitda (earnings before interest, taxes, depreciation, and amortization) is expected to be between 9.7 billion and 10.2 billion euros, slightly higher than the previous projection of 9.5 billion to 10 billion euros. Bayer also raised its guidance for adjusted profit, which is now expected to be between 4.80 and 5.30 euros per share, above the previous forecast of 4.50 to 5.00 euros per share. In the pharmaceuticals division, Bayer revised its expectation for sales growth with currency adjustment upwards to a range of zero to 3%. The previous forecast was for a contraction between 1% and 4%. ...